CU20070114A7 -
RECEPTORS DERIVED FROM 3-PHENYL-PIRAZOL AS MODULATORS OF 5-HT2A SEROTONIN USEFUL IN THE TREATMENT OF DISORDERS RELATED TO THEM
- Google Patents
RECEPTORS DERIVED FROM 3-PHENYL-PIRAZOL AS MODULATORS OF 5-HT2A SEROTONIN USEFUL IN THE TREATMENT OF DISORDERS RELATED TO THEM
Info
Publication number
CU20070114A7
CU20070114A7CU20070114ACU20070114ACU20070114A7CU 20070114 A7CU20070114 A7CU 20070114A7CU 20070114 ACU20070114 ACU 20070114ACU 20070114 ACU20070114 ACU 20070114ACU 20070114 A7CU20070114 A7CU 20070114A7
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmauticals IncfiledCriticalArena Pharmauticals Inc
Priority to CU20070114ApriorityCriticalpatent/CU20070114A7/en
Publication of CU20070114A7publicationCriticalpatent/CU20070114A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención está relacionada con ciertos derivados de 3-fenil-pirazol de fórmula (Ia) y sus composiciones farmacéuticas que modulan la actividad del receptor 5-HT2A de la serotonina. ESPACIO PARA FÓRMULA Los compuestos y sus composiciones farmacéuticas están dirigidos hacia métodos útiles en el tratamiento de la agregación plaquetaria, arteriopatía coronaria, infarto d emiocardio, accidente esquémico transitorio, angina, accidente cerebrovascular, fibrilación auricular, reducción del riesgo de formación de coágulos sanguíneos, asma o sus síntomas, agitación o un síntoma, trastornos de la conducta, psicosis farmacógena, psicosis excitativa, síndrome de Gilles d ela Tourette, trastorno maníaco, psicosis orgánica o sin especificación, trastorno psicótico, psicosis, ezquizofrenia aguda, esquizofrenia crónica, esquizofrenia sin especificación y trastornos relacionados, y trastornos del sueno, Trastornos relacionados con la diabetes, leucoencefalopatíamultifocal prograsiva y semejantes. La presente invención también esta relacionadacon los métodos para el tratamiento de trastornos originados por el receptor 5-HT2A de la seretoninaen combinación con otros agentes farmacéuticos administrados juntos o por separado.The present invention is related to certain 3-phenyl-pyrazole derivatives of formula (Ia) and their pharmaceutical compositions that modulate the activity of the serotonin 5-HT2A receptor. FORMULA SPACE The compounds and their pharmaceutical compositions are directed towards useful methods in the treatment of platelet aggregation, coronary artery disease, heart attack, transient eschemic accident, angina, stroke, atrial fibrillation, reduced risk of blood clot formation, asthma or its symptoms, agitation or a symptom, behavioral disorders, pharmacogenic psychosis, excitative psychosis, Gilles d ela Tourette syndrome, manic disorder, organic or unspecified psychosis, psychotic disorder, psychosis, acute ezchizophrenia, chronic schizophrenia, schizophrenia without specification and related disorders, and sleep disorders, diabetes-related disorders, programmable multifocal leukoencephalopathy and the like. The present invention is also related to methods for the treatment of disorders caused by the 5-HT2A receptor of seretonin in combination with other pharmaceutical agents administered together or separately.
CU20070114A2007-05-182007-05-18
RECEPTORS DERIVED FROM 3-PHENYL-PIRAZOL AS MODULATORS OF 5-HT2A SEROTONIN USEFUL IN THE TREATMENT OF DISORDERS RELATED TO THEM
CU20070114A7
(en)
DERIVATIVES OF DIARIL AND ARILHETEROARIL UREA AS MODULATORS OF THE 5-HT2A SEROTONINE RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED TO THE SAME
Compounds derived from heterocyclic fused imidazole, such as diacylglycerol acyltransferase 2 inhibitors; pharmaceutical composition that includes them, useful for the treatment of type I and II diabetes, coronary heart disease, arthritis, thrombosis, Alzheimer's, among other diseases.
Heterocyclic derivative compounds substituted by carboxamide or sulfonamide, as modulators for the orphan nuclear receptor rorgama; pharmaceutical composition that includes them, useful for the treatment of rheumatoid arthritis, lupus erythematosus, psoriasis, multiple sclerosis, type 1 diabetes, ulcerative colitis, chronic obstructive pulmonary disease, among others.
Compounds derived from 6-triazolopyridazine-sulfanyl benzothiazole and benzimidazole; preparation procedure; intermediate compounds; pharmaceutical composition comprising said compounds; and its use in the treatment of cancer.
COMPOUNDS DERIVED FROM BIFENSUSTUIDAS BY TETRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P2X PURINERGIC RECEPTORS, SUCH AS GASTROINT DISORDERS
COMPOUNDS DERIVED FROM REPLACED HETEROCICLES, ALFA 2C ADRENORECEPTORS AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT ALLERGIC RHINITIS, GLAUCOMA, CONGESTIVE CARDIAC INSUFFICIENCY, ENT SCHIZOPHRENIA
Compounds derived from substituted benzimidazole, preparation process, pharmaceutical composition, useful in the treatment of diseases modulated with antagonists of the fxr receptor, in particular for the treatment of increased levels of lipids and / or cholesterol, atherosclerotic disease, diabetes, cancer, parkinson's , Alzheimer's.
Compounds derived from 2- (3-heteroaryl-amino-1,2,3,4-tetrahydro-9h-carbazole) -acetic acid, pharmaceutical composition that comprises them, and their use as medicines, in the prophylaxis and / or treatment of pathologies mediated by modulation of prostaglandin d2 receptors, such as allergic or immune disorders.